Neutral sphingomyelinase‐2 and cardiometabolic diseases. (18th March 2021)

• Record Type: Journal Article
• Authors: Sindhu, Sardar; Leung, Yat Hei; Arefanian, Hossein; Madiraju, S. R. Murthy; Al‐Mulla, Fahd; Ahmad, Rasheed; Prentki, Marc
• Is Part Of: Obesity reviews. Volume 22:Number 8(2021)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2021-03-18
• Subjects: cardiometabolic diseases -- ceramide -- nSMase2 -- sphingolipid; Obesity -- Periodicals; 616.398005
• DOI: 10.1111/obr.13248
• Languages: English
• ISSNs: 1467-7881

Abstract

Summary: Sphingolipids, in particular ceramides, play vital role in pathophysiological processes linked to metabolic syndrome, with implications in the development of insulin resistance, pancreatic ß‐cell dysfunction, type 2 diabetes, atherosclerosis, inflammation, nonalcoholic steatohepatitis, and cancer. Ceramides are produced by the hydrolysis of sphingomyelin, catalyzed by different sphingomyelinases, including neutral sphingomyelinase 2 (nSMase2), whose dysregulation appears to underlie many of the inflammation‐related pathologies. In this review, we discuss the current knowledge on the biochemistry of nSMase2 and ceramide production and its regulation by inflammatory cytokines, with particular reference to cardiometabolic diseases. nSMase2 contribution to pathogenic processes appears to involve cyclical feed‐forward interaction with proinflammatory cytokines, such as TNF‐α and IL‐1ß, which activate nSMase2 and the production of ceramides, that in turn triggers the synthesis and release of inflammatory cytokines. We elaborate these pathogenic interactions at the molecular level and discuss the potential therapeutic benefits of inhibiting nSMase2 against inflammation‐driven cardiometabolic diseases.